Research Reports | Market Assessment
September 2021

Market Events and Forecast | Respiratory | US/EU5 | 2021

In 2019, sales of branded biologics for respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports